Comparison of two vascular-disrupting agents at a clinically relevant dose in rodent liver tumors with multiparametric magnetic resonance imaging biomarkers

Anti-Cancer Drugs

Volumn 23, Issue 1, 2012, Pages 12-21

  Wang, Huaijun ^a   Cona, Marlein Miranda ^a   Chen, Feng ^a,b   Yu, Jie ^a   Feng, Yuanbo ^a   Li, Junjie ^a   De Keyzer, Frederik ^a   Marchal, Guy ^a   Ni, Yicheng ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b SOUTHEAST UNIVERSITY   (China)

Author keywords

combretastatin A4 phosphate; imaging biomarkers; magnetic resonance imaging; microangiography; tumor; vascular disrupting agent; ZD6126

Indexed keywords

BIOLOGICAL MARKER; COMBRETASTATIN A4 PHOSPHATE; N ACETYLCOLCHINOL PHOSPHATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; DOSE RESPONSE; DRUG EFFICACY; EX VIVO STUDY; HISTOPATHOLOGY; LIVER TUMOR; MALE; MICROANGIOGRAPHY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; REBOUND; RHABDOMYOSARCOMA; TUMOR GROWTH; TUMOR MODEL; TUMOR NECROSIS; TUMOR VASCULARIZATION; TUMOR VOLUME; VALIDATION PROCESS;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CONTRAST MEDIA; DRUG SCREENING ASSAYS, ANTITUMOR; INJECTIONS, INTRAVENOUS; LIVER NEOPLASMS, EXPERIMENTAL; MAGNETIC RESONANCE IMAGING; MALE; MICROVESSELS; NECROSIS; ORGANOPHOSPHORUS COMPOUNDS; RATS; RATS, INBRED STRAINS; RHABDOMYOSARCOMA; STILBENES; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 82555172395     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328349dd60     Document Type: Article

References (51)

1. Denekamp J. Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol 1993; 66:181-196. (Pubitemid 23096969)
2. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer 2005; 5:423-435. (Pubitemid 40791485)
3. Heath VL, Bicknell R. Anticancer strategies involving the vasculature. Nat Rev Clin Oncol 2009; 6:395-404.
4. Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS, Garcia-Kendall D. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia 1989; 45:209-211. (Pubitemid 19062390)
5. Davis PD, Dougherty GJ, Blakey DC, Galbraith SM, Tozer GM, Holder AL, et al. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 2002; 62:7247-7253. (Pubitemid 36025246)
6. Hinnen P, Eskens FA. Vascular disrupting agents in clinical development. Br J Cancer 2007; 96:1159-1165. (Pubitemid 46625071)
7. Robinson SP, McIntyre DJ, Checkley D, Tessier JJ, Howe FA, Griffiths JR, et al. Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging. Br J Cancer 2003; 88:1592-1597. (Pubitemid 36713788)
8. Siemann DW, Chaplin DJ,Walicke PA. A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P). Expert Opin Investig Drugs 2009; 18:189-197.
9. Prise VE, Honess DJ, Stratford MR, Wilson J, Tozer GM. The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses. Int J Oncol 2002; 21:717-726.
10. Bradley DP, Tessier JJ, Ashton SE,Waterton JC,Wilson Z,Worthington PL, et al. Correlation of MRI biomarkers with tumor necrosis in Hras5 tumor xenograft in athymic rats. Neoplasia 2007; 9:382-391. (Pubitemid 46799981)
11. Breidahl T, Nielsen FU, Stodkilde-Jorgensen H, Maxwell RJ, Horsman MR. The effects of the vascular disrupting agents combretastatin A-4 disodium phosphate, 5,6-dimethylxanthenone-4-acetic acid and ZD6126 in a murine tumour: a comparative assessment using MRI and MRS. Acta Oncol 2006; 45:306-316. (Pubitemid 43675572)
12. Hermens AF, Barendsen GW. Cellular proliferation patterns in an experimental rhabdomyosarcoma in the rat. Eur J Cancer 1967; 3:361-369.
13. Chen F, Sun X, De Keyzer F, Yu J, Peeters R, Coudyzer W, et al. Liver tumor model with implanted rhabdomyosarcoma in rats: MR imaging, microangiography, and histopathologic analysis. Radiology 2006; 239:554-562.
14. Madhu B,Waterton JC, Griffiths JR, Ryan AJ, Robinson SP. The response of RIF-1 fibrosarcomas to the vascular-disrupting agent ZD6126 assessed by in-vivo and ex-vivo 1H magnetic resonance spectroscopy. Neoplasia 2006; 8:560-567. (Pubitemid 44061311)
15. Sun X,Wang H, Chen F, De Keyzer F, Yu J, Jiang Y, et al. Diffusion-weighted MRI of hepatic tumor in rats: comparison between in vivo and postmortem imaging acquisitions. J Magn Reson Imaging 2009; 29:621-628.
16. Tofts PS, Berkowitz BA. Rapid measurement of capillary permeability using the early part of the dynamic Gd-DTPA MRI enhancement curve. J Magn Reson B 1993; 102:129-136.
17. Ching LM, Zwain S, Baguley BC. Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice. Br J Cancer 2004; 90:906-910. (Pubitemid 38406605)
18. Seshadri M, Spernyak JA, Maiery PG, Cheney RT, Mazurchuk R, Bellnier DA. Visualizing the acute effects of vascular-targeted therapy in vivo using intravital microscopy and magnetic resonance imaging: correlation with endothelial apoptosis, cytokine induction, and treatment outcome. Neoplasia 2007; 9:128-135.
19. Horsman MR, Murata R. Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response. Int J Radiat Oncol Biol Phys 2003; 57:1047-1055. (Pubitemid 37324123)
20. Murata R, Overgaard J, Horsman MR. Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4- acetic acid on blood perfusion in a murine tumour and normal tissues. Int J Radiat Biol 2001; 77:195-204. (Pubitemid 32158366)
21. Wang H, Sun X, Chen F, De Keyzer F, Yu J, Landuyt W, et al. Treatment of rodent liver tumor with combretastatin A4 phosphate: noninvasive therapeutic evaluation using multiparametric magnetic resonance imaging in correlation with microangiography and histology. Invest Radiol 2009; 44:44-53.
22. Ni Y, Wang H, Chen F, Li J, DeKeyzer F, Feng Y, et al. Tumor models and specific contrast agents for small animal imaging in oncology. Methods 2009; 48:125-138.
23. Chen G, Horsman MR, Pedersen M, Pang Q, Stødkilde-Jørgensen H. The effect of combretastatin A4 disodium phosphate and 5,6- dimethylxanthenone-4-acetic acid on water diffusion and blood perfusion in tumours. Acta Oncol 2008; 47:1071-1076.
24. Delmonte A, Sessa C. AVE8062: a new combretastatin derivative vascular disrupting agent. Expert Opin Investig Drugs 2009; 18:1541-1548.
25. Sheng Y, Hua J, Pinney KG, Garner CM, Kane RR, Prezioso JA, et al. Combretastatin family member OXI4503 induces tumor vascular collapse through the induction of endothelial apoptosis. Int J Cancer 2004; 111:604-610. (Pubitemid 39045329)
26. Kanthou C, Tozer GM. Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies. Int J Exp Pathol 2009; 90:284-294.
27. Siemann DW, ShiW. Dual targeting of tumor vasculature: combining avastin and vascular disrupting agents (CA4P or OXi4503). Anticancer Res 2008; 28:2027-2031.
28. LanduytW, Ahmed B, Nuyts S, Theys J, Op de Beeck M, Rijnders A, et al. Invivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment. Int J Radiat Oncol Biol Phys 2001; 49:443-450. (Pubitemid 32120242)
29. Murata R, Overgaard J, Horsman MR. Combretastatin A-4 disodium phosphate: a vascular targeting agent that improves that improves the antitumor effects of hyperthermia, radiation, and mild thermoradiotherapy. Int J Radiat Oncol Biol Phys 2001; 51:1018-1024. (Pubitemid 33026433)
30. Blakey DC, Ashton SE,Westwood FR,Walker M, Ryan AJ. ZD6126: a novel small molecule vascular targeting agent. Int J Radiat Oncol Biol Phys 2002; 54:1497-1502. (Pubitemid 35380055)
31. Siemann DW. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumor-vascular disrupting agents. Cancer Treat Rev 2011; 37:63-74.
32. Micheletti G, Poli M, Borsotti P, Martinelli M, Imberti B, Taraboletti G, et al. Vascular-targeting activity of ZD6126, a novel tubulin-binding agent. Cancer Res 2003; 63:1534-1537. (Pubitemid 36373640)
33. Lippert JW 3rd. Vascular disrupting agents. Bioorg Med Chem 2007; 15:605-615. (Pubitemid 44880701)
34. Tozer GM, Kanthou C, Lewis G, Prise C, Vojnovic B, Hill SA. Tumour vascular disrupting agents: combating treatment resistance. Br J Radiol 2008; 81:S12-S20.
35. Sheng Y, Hua J, Pinney KG, Garner CM, Kane RR, Prezioso JA, et al. Combretastatin family member OXI4503 induces tumor vascular collapse through the induction of endothelial apoptosis. Int J Cancer 2004; 111:604-610. (Pubitemid 39045329)
36. Dachs GU, Steele AJ, Coralli C, Kanthou C, Brooks AC, Gunningham SP, et al. Anti-vascular agent combretastatin A-4-P modulates hypoxia inducible factor-1 and gene expression. BMC Cancer 2006; 6:280.
37. Wang H, Li J, Chen F, De Keyzer F, Yu J, Feng Y, et al. Morphological, functional and metabolic imaging biomarkers: assessment of vasculardisrupting effect on rodent liver tumours. Eur Radiol 2010; 20:2013-2026.
38. Miller AB, Hoogstraten B, Staquet M,Winkler A. Reporting results of cancer treatment. Cancer 1981; 47:207-214. (Pubitemid 11167383)
39. Therasse P, Arbuck SG, Eisenhauer EA,Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216. (Pubitemid 30099779)
40. Padhani AR, Miles KA. Multiparametric imaging of tumor response to therapy. Radiology 2010; 256:348-364.
41. Harry VN, Semple SI, Parkin DE, Gilbert FJ. Use of new imaging techniques to predict tumour response to therapy. Lancet Oncol 2010; 11:92-102.
42. Tozer GM. Measuring tumour vascular response to antivascular and antiangiogenic drugs. Br J Radiol 2003; 76:S23-S35. (Pubitemid 39530313)
43. Jordan BF, Gallez B. Surrogate MR markers of response to chemo- or radiotherapy in association with co-treatments: a retrospective analysis of multi-modal studies. Contrast Media Mol Imaging 2010; 5:323-332.
44. Lang P, Wendland MF, Saeed M, Gindele A, Rosenau W, Mathur A, et al. Osteogenic sarcoma: noninvasive in vivo assessment of tumor necrosis with diffusion-weighted MR imaging. Radiology 1998; 206:227-235.
45. Thoeny HC, Ross BD. Predicting and monitoring cancer treatment response with diffusion-weighted MRI. J Magn Reson Imaging 2010; 32:2-16.
46. Padhani AR, Liu G, Mu-Koh D, Chenevert TL, Thoeny HC, Takahara T, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 2009; 11:102-125.
47. Tofts PS. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 1997; 7:91-101. (Pubitemid 28365643)
48. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)- weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999; 10:223-232. (Pubitemid 29463104)
49. Collins DJ, Padhani AR. Dynamic magnetic resonance imaging of tumor perfusion: approaches and biomedical challenges. IEEE Eng Med Biol Mag 2004; 23:65-83. (Pubitemid 39545969)
50. Jackson A, O'Connor JP, Parker GJ, Jayson GC. Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging. Clin Cancer Res 2007; 13:3449-3459. (Pubitemid 46955104)
51. Koh DM, Blackledge M, Collins DJ, Padhani AR, Wallace T,Wilton B, et al. Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial. Eur Radiol 2009; 19: 2728-2738.